DBV Technologies | DBVT - Debt


DBV Technologies reported $8.59M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 56.29M 1.36M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amarin USD 0 0 Mar/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
DBV Technologies USD 8.59M 295K Sep/2025
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Incyte USD 42.41M 5.29M Jun/2025
Insmed USD 564.56M 464K Sep/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
United Therapeutics USD 200M 100M Mar/2025